Bucindolol is a beta-adrenergic receptor antagonist. Bucindolol is a fourth-generation β-blocker. Bucindolol prevented new-onset AF; β₁ and α(2c) polymorphisms predicted therapeutic response; and the 47% of patients who were β₁389 Arg homozygotes had an e